Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month High on Analyst Upgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) shares hit a new 52-week high on Friday after Stifel Nicolaus raised their price target on the stock from $60.00 to $65.00. Stifel Nicolaus currently has a buy rating on the stock. Apellis Pharmaceuticals traded as high as $70.00 and last traded at $68.95, with a volume of 45659 shares traded. The stock had previously closed at $68.53.

Several other equities research analysts have also recently weighed in on the stock. Oppenheimer boosted their price target on shares of Apellis Pharmaceuticals from $68.00 to $78.00 and gave the stock an “outperform” rating in a research report on Thursday, August 18th. Citigroup boosted their price objective on shares of Apellis Pharmaceuticals from $81.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, July 20th. HC Wainwright initiated coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 19th. They set a “buy” rating and a $75.00 price objective on the stock. The Goldman Sachs Group boosted their price objective on shares of Apellis Pharmaceuticals from $91.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, Raymond James boosted their price objective on shares of Apellis Pharmaceuticals from $102.00 to $113.00 and gave the company a “strong-buy” rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $72.93.

Insider Buying and Selling

In related news, Director A. Sinclair Dunlop sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $65.63, for a total value of $1,968,900.00. Following the completion of the sale, the director now directly owns 255,679 shares of the company’s stock, valued at $16,780,212.77. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director A. Sinclair Dunlop sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $65.63, for a total value of $1,968,900.00. Following the completion of the sale, the director now directly owns 255,679 shares of the company’s stock, valued at $16,780,212.77. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mark Jeffrey Delong sold 10,000 shares of the stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $41.78, for a total transaction of $417,800.00. Following the sale, the senior vice president now directly owns 29,250 shares of the company’s stock, valued at $1,222,065. The disclosure for this sale can be found here. Insiders sold a total of 142,289 shares of company stock valued at $8,071,218 over the last three months. 8.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently modified their holdings of APLS. US Bancorp DE increased its holdings in shares of Apellis Pharmaceuticals by 391.2% during the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after acquiring an additional 884 shares in the last quarter. S.A. Mason LLC increased its holdings in Apellis Pharmaceuticals by 15.1% in the 2nd quarter. S.A. Mason LLC now owns 3,160 shares of the company’s stock worth $143,000 after buying an additional 415 shares during the period. Dupont Capital Management Corp acquired a new position in Apellis Pharmaceuticals in the 1st quarter worth approximately $161,000. Great West Life Assurance Co. Can increased its holdings in Apellis Pharmaceuticals by 15.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,734 shares of the company’s stock worth $202,000 after buying an additional 500 shares during the period. Finally, Mackenzie Financial Corp acquired a new position in Apellis Pharmaceuticals in the 1st quarter worth approximately $206,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

Apellis Pharmaceuticals Trading Down 1.4 %

The company’s fifty day moving average is $57.92 and its two-hundred day moving average is $50.08. The company has a debt-to-equity ratio of 0.57, a quick ratio of 7.19 and a current ratio of 7.57. The company has a market cap of $7.42 billion, a price-to-earnings ratio of -9.98 and a beta of 1.51.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last issued its quarterly earnings results on Monday, August 8th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.03). Apellis Pharmaceuticals had a negative return on equity of 272.25% and a negative net margin of 660.59%. During the same quarter last year, the company posted ($2.72) earnings per share. On average, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -5.92 EPS for the current year.

Apellis Pharmaceuticals Company Profile

(Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Featured Stories

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.